Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: Recommendation from a 22-year follow-up of 18 patients

Cancer

Volumn 113, Issue 8, 2008, Pages 2020-2028

  Huang, Hui ^a   Abraham, Jame ^b   Hung, Elizabeth ^a   Averbuch, Steven ^c   Merino, Maria ^a   Steinberg, Seth M ^a   Pacak, Karel ^d   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Cyclophosphamide; Dacarbazine; Paraganglioma; Pheochromocytoma; Vincristine

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; CATECHOLAMINE; CLONIDINE; CYCLOPHOSPHAMIDE; DACARBAZINE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; METIROSINE; PHENOXYBENZAMINE; PRAZOSIN; PROPRANOLOL; VERAPAMIL; VINCRISTINE;

ADULT; ARTICLE; BLOOD PRESSURE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARDIOGENIC SHOCK; CATECHOLAMINE RELEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; HYPOTENSION; MALE; METASTASIS; NEUROLOGICAL SIDE EFFECT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARAGANGLIOMA; PERIPHERAL NEUROPATHY; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYCLOPHOSPHAMIDE; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; TREATMENT OUTCOME; VINCRISTINE;

EID: 55749091604     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23812     Document Type: Article

References (52)

1. Townsend CM, Sabiston DC. Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice. 17th ed. Philadelphia, PA: Elsevier Saunders; 2004.
2. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58:802-804.
3. Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand. 1986;220:225-232.
4. Hartley L, Perry-Keene D. Phaeochromocytoma in Queensland - 1970-83. Aust N Z J Surg. 1985;55:471-475.
5. Andersen GS, Toftdahl DB, Lund JO, Strandgaard S, Nielsen PE. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J Hum Hypertens. 1988;2:187-189.
6. Fernandez-Calvet L, Garcia-Mayor RV. Incidence of pheochromocytoma in South Galicia, Spain. J Intern Med. 1994;236:675-677.
7. Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of 1 institution's experience. Medicine (Baltimore). 1991;70:46-66.
8. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315-329.
9. Yeo H, Roman S. Pheochromocytoma and functional paraganglioma. Curr Opin Oncol. 2005;17:13-18.
10. Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991;40:544-556.
11. Plouin PF, Chatellier G, Fofol I, Corvol P. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997;29:1133-1139.
12. Goldstein RE, O'Neill JA Jr, Holcomb GW III, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229:755-764; discussion 64-66.
13. Mannelli M, Ianni L, Cilotti A, Conti A. Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol. 1999;141:619-624.
14. O'Riordain DS, Young WF Jr, Grant CS, Carney JA, van Heerden JA. Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg. 1996;20:916-921.
15. Edstrom Elder E, Hjelm Skog AL, Hoog A, Hamberger B. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol. 2003;29:278-283.
16. Glodny B, Winde G, Herwig R, Meier A, Kuhle C, Cromme S, et al. Clinical differences between benign and malignant pheochromocytomas. Endocr J. 2001;48:151-159.
17. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812-8818.
18. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 2003;63:5615-5621.
19. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943-951.
20. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab. 2006;91:827-836.
21. Timmers HJ, Kozupa A, Eisenhofer G, et al. Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2007;92:779-786.
22. Brouwers FM, Eisenhofer G, Tao JJ, et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab. 2006;91:4505-4509.
23. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665-675.
24. Motta-Ramirez GA, Remer EM, Herts BR, Gill IS, Hamrahian AH. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am J Roentgenol. 2005;185:684-688.
25. Young WF Jr, Maddox DE. Spells: in search of a cause. Mayo Clin Proc. 1995;70:757-765.
26. Thompson GB, Young WF Jr. Adrenal incidentaloma. Curr Opin Oncol. 2003;15:84-90.
27. Raber W, Raffesberg W, Bischof M, et al. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med. 2000;160:2957-2963.
28. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001;86:1480-1486.
29. Kinney MA, Warner ME, vanHeerden JA, et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg. 2000;91:1118-1123.
30. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004;11:423-436.
31. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24:539-553.
32. Remine WH, Chong GC, Van Heerden JA, Sheps SG, Harrison EG Jr. Current management of pheochromocytoma. Ann Surg. 1974;179:740-748.
33. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology. 1999;53:679-683.
34. van Heerden JA, Sheps SG, Hamberger B, Sheedy PF II, Poston JG, ReMine WH. Pheochromocytoma: current status and changing trends. Surgery. 1982;91:367-373.
35. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988;109:267-273.
36. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710-719.
37. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
38. Mantel N. Evaluation of survival data and 2 new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
39. Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev. 1994;15:356-368.
40. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest. 1992;15:631-642.
41. Scott HW Jr, Reynolds V, Green N, et al. Clinical experience with malignant pheochromocytomas. Surg Gynecol Obstet. 1982;154:801-818.
42. Lewi HJ, Reid R, Mucci B, et al. Malignant phaeochromocytoma. Br J Urol. 1985;57:394-398.
43. Voorhess ML. The catecholamines in tumor and urine from patients with neuroblastoma, ganglioneuroblastoma and pheochromocytoma. J Pediatr Surg. 1968;3:147-148.
44. Kato K, Asano T, Kamiya N, et al. Production of the alpha subunit of guanine nucleotide-binding protein GO by neuroendocrine tumors. Cancer Res. 1987;47:5800-5805.
45. Pauwels O, Gozy M, Van Houtte P, Pasteels JL, Atassi G, Kiss R. Cross resistance and collateral sensitivity between cytotoxic drugs and radiation in 2 human bladder cell lines. Radiother Oncol. 1996;39:81-86.
46. Dobrzynska MM. The effects in mice of combined treatments to X-rays and antineoplastic drugs in the Comet assay. Toxicology. 2005;207:331-338.
47. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs. 1997;8:92-97.
48. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92:4069-4079.
49. Srimuninnimit V, Wampler GL. Case report of metastatic familial pheochromocytoma treated with cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol. 1991;28:217-219.
50. Jirari A, Charpentier A, Popescu S, Boidin P, Eisenmann B. A malignant primary cardiac pheochromocytoma. Ann Thorac Surg. 1999;68:565-566.
51. Nakane M, Takahashi S, Sekine I, et al. Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline. Ann Oncol. 2003;14:1449-1451.
52. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401-406.